Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content

06 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/06/3213529/0/en/Cogent-Biosciences-Announces-Presentation-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html

30 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/30/3211356/0/en/Cogent-Biosciences-Announces-Submission-of-New-Drug-Application-for-Bezuclastinib-in-NonAdvanced-Systemic-Mastocytosis.html

08 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/08/3201431/0/en/Cogent-Biosciences-Announces-Positive-Top-line-Results-of-APEX-Trial-of-Bezuclastinib-in-Patients-with-Advanced-Systemic-Mastocytosis-AdvSM.html

06 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/06/3201063/0/en/Cogent-Biosciences-Presents-Full-SUMMIT-Results-of-Bezuclastinib-in-Patients-with-NonAdvanced-Systemic-Mastocytosis-NonAdvSM-at-the-67th-Annual-Meeting-of-the-American-Society-of-H.html

14 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/14/3188255/0/en/Cogent-Biosciences-Announces-Participation-in-the-Jefferies-Global-Healthcare-Conference.html

12 Nov 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/cogent-eyes-fda-submission-cancer-asset-after-clearing-another-phase-3-hurdle
ABOUT THIS PAGE